Galderma Group AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: $22.9B

Website: http://www.galderma.com/

Clinical Trials

Study to Evaluate Efficacy, Safety and Injection Technique of Restylane Lip Volume and Restylane Lip Refresh

Not Applicable

Completed

Conditions: Injection Techniques

Interventions: Device: Restylane Lip Volume
Device: Restylane Lip Refresh

First Posted Date: 2011-09-02

Last Posted Date: 2022-08-26

Lead Sponsor: Galderma R&D

Target Recruit Count: 60

Registration Number: NCT01428024

Locations: 🇸🇪
Akademikliniken, Stockholm, Sweden
🇸🇪
Stureplanskliniken, Stockholm, Sweden
🇸🇪
Göteborgs Plastikkirurgiska Center, Göteborg, Sweden

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

Phase 4

Completed

Conditions: Rosacea

Interventions: Drug: Placebo
Drug: Doxycycline
Drug: Metronidazole

First Posted Date: 2011-08-31

Last Posted Date: 2022-08-01

Lead Sponsor: Galderma R&D

Target Recruit Count: 235

Registration Number: NCT01426269

Locations: 🇺🇸
ATS Clinical Research, Santa Monica, California, United States
🇺🇸
Melissa L. F. Knuckles M.D., P.S.C., Richmond, Kentucky, United States
🇺🇸
Dadeland Dermatology, Coral Gables, Florida, United States

and more 7 locations

Study to Evaluate Restylane Vital Light Using an Injector Device

Not Applicable

Completed

Conditions: Aesthetics

Interventions: Other: No treatment
Device: Restylane Vital Light

First Posted Date: 2011-08-09

Last Posted Date: 2022-08-25

Lead Sponsor: Galderma R&D

Target Recruit Count: 30

Registration Number: NCT01412190

Locations: 🇩🇪
University of Hamburg, Hamburg, Germany

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Phase 3

Completed

Conditions: Rosacea

Interventions: Drug: CD07805/47 Gel
Drug: Placebo

First Posted Date: 2011-05-18

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 293

Registration Number: NCT01355471

Locations: 🇺🇸
Haber Dermatology & Cosmetic Surgery, South Euclid, Ohio, United States
🇺🇸
Central Dermatology PC, Saint Louis, Missouri, United States
🇺🇸
Skin Specialty Dermatology, New York, New York, United States

and more 12 locations

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Phase 3

Completed

Conditions: Rosacea

Interventions: Drug: CD07805/47 gel
Drug: Placebo

First Posted Date: 2011-05-18

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 260

Registration Number: NCT01355458

Locations: 🇺🇸
Oregon Medical Research Center, Portland, Oregon, United States
🇨🇦
Innovaderm Research, Inc, Montreal, Quebec, Canada
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 12 locations

A Study to Evaluate Efficacy and Safety of Macrolane VRF30 for Volume Restoration and Contouring of the Buttocks

Phase 4

Completed

Conditions: Volume Restoration and Shaping of the Buttocks

Interventions: Device: Macrolane VRF30

First Posted Date: 2011-04-08

Last Posted Date: 2022-09-28

Lead Sponsor: Galderma R&D

Target Recruit Count: 61

Registration Number: NCT01331408

Locations: 🇪🇸
Centro Clinico Mir-Mir, Barcelona, Spain
🇸🇪
Akademikliniken, Stockholm, Sweden
🇪🇸
Cirugia Plastica, Madrid, Spain

and more 1 locations

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Doxycycline 100 mg
Drug: CD2475/101 40 mg
Drug: Placebo

First Posted Date: 2011-03-22

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 662

Registration Number: NCT01320033

Locations: 🇺🇸
Haber Dermatology & cosmetic Surgery, Inc, South Euclid, Ohio, United States
🇺🇸
PMG Research of Wilmington, Wilmington, North Carolina, United States
🇺🇸
Stephen Schleicher, Hazleton, Pennsylvania, United States

and more 28 locations

Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Phase 3

Completed

Conditions: Rosacea

Interventions: Drug: CD07805/47 gel 0.5%

First Posted Date: 2011-03-18

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 449

Registration Number: NCT01318733

Locations: 🇺🇸
DermResearch Center of New York, Inc, Stony Brook, New York, United States
🇺🇸
Rivergate Dermatology Clinical Research Center, PLLC, Goodlettsville, Tennessee, United States
🇺🇸
Wenatchee Valley Medical Center - Clinical Research Department, Wenatchee, Washington, United States

and more 24 locations

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

Phase 4

Completed

Conditions: Rosacea

Interventions: Other: Placebo
Drug: Doxycycline

First Posted Date: 2011-03-04

Last Posted Date: 2022-08-01

Lead Sponsor: Galderma R&D

Target Recruit Count: 170

Registration Number: NCT01308619

Locations: 🇺🇸
Michigan Center for Research Corp, Clinton Township, Michigan, United States
🇺🇸
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
🇺🇸
Oregon Medical Research Center, PC, Portland, Oregon, United States

and more 7 locations

Macrolane for Enhancement of the Shape and Fullness of the Female Breast

Not Applicable

Completed

Conditions: Breast Enhancement

Interventions: Device: Macrolane

First Posted Date: 2011-03-04

Last Posted Date: 2022-09-28

Lead Sponsor: Galderma R&D

Target Recruit Count: 24

Registration Number: NCT01308853

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy